BlackRock Japan’s Vertex Pharmaceuticals VRTX Stock Holding History

BlackRock Japan’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$23.7M	Buy	321,519 +2,324	+0.7%	+$189K	0.08%	284
2016 Q3	$27.8M	Buy	319,195 +6,474	+2%	+$612K	0.1%	250
2016 Q2	$26.9M	Buy	312,721 +1,437	+0.5%	+$124K	0.1%	251
2016 Q1	$24.7M	Buy	311,284 +8,992	+3%	+$813K	0.09%	249
2015 Q4	$38M	Sell	302,292 -1,763	-0.6%	-$213K	0.14%	163
2015 Q3	$31.7M	Buy	304,055 +209	+0.1%	+$26.9K	0.13%	185
2015 Q2	$37.5M	Buy	303,846 +13,301	+5%	+$1.68M	0.14%	167
2015 Q1	$34.3M	Sell	290,545 -11,680	-4%	-$1.4M	0.14%	180
2014 Q4	$35.9M	Buy	302,225 +26,776	+10%	+$3.02M	0.14%	180
2014 Q3	$30.9M	Buy	275,449 +17,835	+7%	+$1.7M	0.13%	178
2014 Q2	$24.4M	Sell	257,614 -22,212	-8%	-$1.56M	0.11%	212
2014 Q1	$19.8M	Buy	279,826 +13,792	+5%	+$1.09M	0.09%	268
2013 Q4	$19.8M	Sell	266,034 -38,726	-13%	-$2.7M	0.09%	257
2013 Q3	$23.1M	Buy	304,760 +47,255	+18%	+$3.76M	0.11%	216
2013 Q2	$20.6M	Buy	+257,505	New	+$19M	0.09%	247

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Japan's VRTX Position: Q4 2016 in Review

BlackRock Japan increased its Vertex Pharmaceuticals (VRTX) stake by 0.73% in Q4 2016, buying an estimated $189K and bringing the position to 321,519 shares worth $23.7M. The position accounts for 0.08% of the portfolio, ranked #284.

BlackRock Japan first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $38M in Q4 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

BlackRock Japan held 321,519 shares of Vertex Pharmaceuticals worth $23.7M as of Q4 2016.
BlackRock Japan bought 2,324 Vertex Pharmaceuticals shares in Q4 2016, an estimated $189K.
Vertex Pharmaceuticals made up 0.08% of BlackRock Japan's portfolio in Q4 2016, its #284 holding.
BlackRock Japan first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Japan's Vertex Pharmaceuticals position peaked at $38M in Q4 2015.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.